Abstract
Dipeptidyl peptidase IV (DPP IV) is a validated target for the treatment of type 2 diabetes, with several inhibitors currently in phase 3 clinical trials. This review will mainly focus on proline-specific dipeptidyl peptidases related to DPP IV: fibroblast activation protein (FAP), dipeptidyl peptidase 8 (DPP8), dipeptidyl peptidase 9 (DPP9) and dipeptidyl peptidase II (DPP II). The biochemical and biological properties of these enzymes will be discussed, as well as the therapeutic potential of their inhibition. The development of potent and selective inhibitors for each of these peptidases will be described.
Keywords: Dipeptidyl peptidase, DPP IV, DPP II, DPP8, DPP9, FAP, medicinal chemistry
Current Topics in Medicinal Chemistry
Title: Prolyl Peptidases Related to Dipeptidyl Peptidase IV: Potential of Specific Inhibitors in Drug Discovery.
Volume: 7 Issue: 6
Author(s): Pieter Van der Veken, Achiel Haemers and Koen Augustyns
Affiliation:
Keywords: Dipeptidyl peptidase, DPP IV, DPP II, DPP8, DPP9, FAP, medicinal chemistry
Abstract: Dipeptidyl peptidase IV (DPP IV) is a validated target for the treatment of type 2 diabetes, with several inhibitors currently in phase 3 clinical trials. This review will mainly focus on proline-specific dipeptidyl peptidases related to DPP IV: fibroblast activation protein (FAP), dipeptidyl peptidase 8 (DPP8), dipeptidyl peptidase 9 (DPP9) and dipeptidyl peptidase II (DPP II). The biochemical and biological properties of these enzymes will be discussed, as well as the therapeutic potential of their inhibition. The development of potent and selective inhibitors for each of these peptidases will be described.
Export Options
About this article
Cite this article as:
Van der Veken Pieter, Haemers Achiel and Augustyns Koen, Prolyl Peptidases Related to Dipeptidyl Peptidase IV: Potential of Specific Inhibitors in Drug Discovery., Current Topics in Medicinal Chemistry 2007; 7 (6) . https://dx.doi.org/10.2174/156802607780091046
DOI https://dx.doi.org/10.2174/156802607780091046 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
Call for Papers in Thematic Issues
Medicinal Chemistry Advancement in Life-Threatening Diseases
The current issue will highlight concise reports that specify ground-breaking insights, including the novel discovery of drug targets and their action mechanism or drugs of novel classes. These are projected to encourage medicinal chemistry future efforts to address the most challenging medical needs. The current issue highlights further efforts to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Inhibitors of HDACs - Effective Drugs Against Cancer?
Current Cancer Drug Targets QSAR study on N- (Aryl)-4-(Azolylethyl) Thiazole-5-Carboxamides: Novel Potent Inhibitors of VEGF Receptors I and II
Medicinal Chemistry Flavonoids and other Non-alkaloidal Constituents of Genus Erythrina: Phytochemical Review
Combinatorial Chemistry & High Throughput Screening DLEU2: A Meaningful Long Noncoding RNA in Oncogenesis
Current Pharmaceutical Design Recent Advances of p53-MDM2 Small Molecule Inhibitors (2011-Present)
Current Medicinal Chemistry Role of Fractalkine (CX3CL1) in Regulating Neuron-Microglia Interactions: Development of Viral-Based CX3CR1 Antagonists
Current Alzheimer Research Targeting Heme Oxygenase-1 for Neuroprotection and Neuroinflammation in Neurodegenerative Diseases
Current Drug Targets The HIV-1 Capsid Protein as a Drug Target: Recent Advances and Future Prospects
Current Protein & Peptide Science TRP Channels and Cancer: New Targets for Diagnosis and Chemotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Inhibitors of HIV-1 Protease: Current State of the Art 10 Years After their Introduction. From Antiretroviral Drugs to Antifungal, Antibacterial and Antitumor Agents Based on Aspartic Protease Inhibitors
Current Medicinal Chemistry From Na+/K+-ATPase and Cardiac Glycosides to Cytotoxicity and Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Non-steroidal Anti-Inflammatory Drugs and Melanoma
Current Pharmaceutical Design On the Origin of Epidermal Cancers
Current Molecular Medicine Nanomaterials for Photohyperthermia: A Review
Current Pharmaceutical Design Need to Think Outside Organ-based Diagnosis to Molecular Diagnostics
Applied Clinical Research, Clinical Trials and Regulatory Affairs Developments of Combretastatin A-4 Derivatives as Anticancer Agents
Current Medicinal Chemistry Perspectives on Medicinal Properties of Benzoquinone Compounds
Mini-Reviews in Medicinal Chemistry The Histone Deacetylase Inhibitor, MS-275 (Entinostat), Downregulates c-FLIP, Sensitizes Osteosarcoma Cells to FasL, and Induces the Regression of Osteosarcoma Lung Metastases
Current Cancer Drug Targets Plant Cells as Pharmaceutical Factories
Current Pharmaceutical Design The Adjunctive Value of Diffusion Weighted Imaging in Diagnosis and Follow Up of Uterovaginal Diffuse B-cell Lymphoma: A Case Report and Literature Review
Current Medical Imaging